Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

Patients with a longer duration of GLP-1 RA treatment (odds ratio [OR], 1.014) and higher Homeostasis Model Assessment of Beta-Cell Function levels (OR, 4.912) were more likely to achieve ...

Both groups had a median follow-up of 365 days. Patients in the GLP-1 RA group were significantly less likely to require any medication than those in the control group (29.7% vs 56.4%; P < .001).

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed ...

Mechanism of Action Relevant to AUD GLP-1 is an incretin hormone that influences insulin secretion and appetite regulation. However, GLP-1 receptors are also found in brain regions associated with ...

Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND ...

It suggested that exenatide, another GLP-1 drug, lowers brain pressure. Of note the drug seemed to reduce migraine days among the study participants, although it was unable to show a strong ...

(HealthDay News) — In 2024, 26.5 percent of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables, according to an August data brief published by the ...

A matched cohort of 139,002 patients was created, with 46,334 patients exposed to GLP-1 RAs and 92,668 unexposed patients.

Adolescent use of GLP-1 receptor agonist (RA) drugs for weight-loss surged since the American Academy of Pediatrics changed guidelines in 2023 to recommend offering weight-loss medications ...